Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Breo Inverts Traditional Path To COPD Indication For LABA Combinations

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GlaxoSmithKline’s NDA for Breo Ellipta sought a COPD indication without prior approval of the combination product or its individual inhaled corticosteroid and long-acting beta agonist components in asthma. A broad development program with extensive dose finding won over a skeptical FDA.


Related Content

Review Of Reviews: Drug Review Profiles 2013
Review Of Reviews: Drug Review Profiles 2013
GSK’s Anoro Ellipta Heads To FDA Panel With Higher Hopes For Higher Dose
Two Claims Allow GSK To Show Benefit For Each Breo Component In COPD
GSK’s Prices Breo On Par With Advair For COPD
New COPD Candidates Could Get Hung Up On Safety Concerns
Boehringer’s Novel Exercise Claims In COPD May Spur FDA Action To Clarify Requirements
FDA Supersizes Its Order For LABA Safety Studies


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts